Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205647 · ClinicalTrials.gov registry record · Phase 2
Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis
A Phase 2 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00205647 is a Phase 2 study that has completed, run by Wake Forest University. The registered enrollment target is 240 participants.
The verdict
NCT00205647, a Phase 2 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity. We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis, particularly the incidence of acute exacerbations.
Interventions
- DRUG Oral N-acetycystein (NAC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 1997-01 |
| Est. Completion | 2000-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205647
The ClinicalTrials.gov registry entry for NCT00205647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral N-acetycystein (NAC) is the first listed.
NCT00205647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205647 about?
NCT00205647 is a clinical study titled "Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis". This is a randonmized, masked, placebo-controlled parallel group, clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine (NAC) and placebo on patient safety and on physical and transport properties of expectorated sputum. Patient sumptoms, quality of life and exacerba...
What is the current status of trial NCT00205647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 1997-01. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00205647?
The interventions under investigation include: Oral N-acetycystein (NAC) (DRUG).
Who is sponsoring clinical trial NCT00205647?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.